tiprankstipranks

Michael G. Carter Insider Profile

4 Followers
Michael G. Carter, Director at Oncternal Therapeutics, holds 71.95K shares in Oncternal Therapeutics (Ticker: ONCT), holds 0.00 shares in Santarus (Ticker: SNTS). Most recently, Michael G. Carter Bought ― shares of Oncternal Therapeutics on Sep 02, 2020 for an estimated value of 150.00K.
tipranks
Michael G. Carter

Michael G. Carter
Oncternal Therapeutics (ONCT)
Director

Not Ranked
Michael G. Carter has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$619K
100.00%
A breakdown of Michael G. Carter's holdings

Insider Roles

Oncternal Therapeutics
(ONCT)
Director
Roles that Michael G. Carter holds in companies

Most Profitable Insider Trade

Stock:
Oncternal Therapeutics
(ONCT)
Rating:Informative Buy
Date:Sep 02, 2020 - Sep 02, 2021
Return:+113.20%
The most profitable trade made by Michael G. Carter

Michael G. Carter's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Oncternal Therapeutics
Sep 02, 2020
Director
Informative Buy
150.00K
$618.74K
SNTS
Santarus
List of latest transactions for each holding click on a transaction to see Michael G. Carter's performance on stock

Michael G. Carter insider profile FAQ

What is the percentage of profitable transactions made by Michael G. Carter?
The percentage of profitable transactions made by Michael G. Carter is ―.
    What is the average return per transaction made by Michael G. Carter?
    The average return per transaction made by Michael G. Carter is ―.
      What stocks does Michael G. Carter hold?
      Michael G. Carter holds: ONCT, SNTS stocks.
        What was Michael G. Carter’s latest transaction?
        Michael G. Carter latest transaction was an Informative Buy of $150.00K.
          What was Michael G. Carter's most profitable transaction?
          Michael G. Carter’s most profitable transaction was an Informative Buy of ONCT stock on September 2, 2020. The return on the trade was 113.20%.
            What is Michael G. Carter's role in Oncternal Therapeutics?
            Michael G. Carter's role in Oncternal Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.